Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
Chinese Patent Office
Deloitte
Teva
UBS
Federal Trade Commission
Fish and Richardson
Accenture
Merck

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,246,979

« Back to Dashboard

Which drugs does patent 8,246,979 protect, and when does it expire?

Patent 8,246,979 protects NEUPRO and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.
Summary for Patent: 8,246,979
Title:Transdermal delivery system for the administration of rotigotine
Abstract: An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains rotigotine in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of rotigotine and is impermeable to the protonated form of rotigotine.
Inventor(s): Schacht; Dietrich Wilhelm (Koln, DE), Hannay; Mike (Wachtberg-Villiprott, DE), Wolff; Hans-Michael (Monheim, DE)
Assignee: UCB Pharma GmbH (Monheim, DE)
Application Number:10/623,864
Patent Claim Types:
see list of patent claims
Delivery; Use;

Drugs Protected by US Patent 8,246,979

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-004 Apr 2, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-004 Apr 2, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-001 May 9, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-001 May 9, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-002 May 9, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-002 May 9, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-003 May 9, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM ➤ Sign Up
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-003 May 9, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,246,979

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02016860Jul 30, 2002

Non-Orange Book US Patents Family Members for Patent 8,246,979

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,617,591 Transdermal delivery system for the administration of rotigotine ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,246,979

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland 217079 ➤ Sign Up
Poland 374814 ➤ Sign Up
Norway 333297 ➤ Sign Up
Norway 20050472 ➤ Sign Up
Mexico PA05000350 ➤ Sign Up
South Korea 101016838 ➤ Sign Up
South Korea 20050056942 ➤ Sign Up
Japan 5564469 ➤ Sign Up
Japan 2011219485 ➤ Sign Up
Japan 4837916 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
US Army
Julphar
Cerilliant
US Department of Justice
Queensland Health
UBS
Cantor Fitzgerald
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot